An Economic Analysis of SC24 in Canada: A Randomized Study of SBRT Compared With Conventional Palliative RT for Spinal Metastases

The Canadian Cancer Trials Group (CCTG) Symptom Control 24 protocol (SC.24) was a multicenter randomized controlled phase 2/3 trial conducted in Canada and Australia. Patients with painful spinal metastases were randomized to either 24 Gy/2 stereotactic body radiation therapy (SBRT) or 20 Gy/5 conve...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of radiation oncology, biology, physics biology, physics, 2024-07, Vol.119 (4), p.1061-1068
Hauptverfasser: Kerba, Marc, Lourenco, Richard De Abreu, Sahgal, Arjun, Cardet, Rafael De Feria, Siva, Shankar, Ding, Keyue, Myrehaug, Sten D, Masucci, Giuseppina L., Brundage, Michael, Parulekar, Wendy R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1068
container_issue 4
container_start_page 1061
container_title International journal of radiation oncology, biology, physics
container_volume 119
creator Kerba, Marc
Lourenco, Richard De Abreu
Sahgal, Arjun
Cardet, Rafael De Feria
Siva, Shankar
Ding, Keyue
Myrehaug, Sten D
Masucci, Giuseppina L.
Brundage, Michael
Parulekar, Wendy R.
description The Canadian Cancer Trials Group (CCTG) Symptom Control 24 protocol (SC.24) was a multicenter randomized controlled phase 2/3 trial conducted in Canada and Australia. Patients with painful spinal metastases were randomized to either 24 Gy/2 stereotactic body radiation therapy (SBRT) or 20 Gy/5 conventional external beam radiation therapy (CRT). The study met its primary endpoint and demonstrated superior complete pain response rates at 3 months following SBRT (35%) versus CRT (14%). SBRT planning and delivery is resource intensive. Given its benefits in SC.24, we performed an economic analysis to determine the incremental cost-effectiveness of SBRT compared with CRT. The trial recruited 229 patients. Cost-effectiveness was assessed using a Markov model taking into account observed survival, treatments costs, retreatment, and quality of life over the lifetime of the patient. The EORTC-QLU-C10D was used to determine quality of life values. Transition probabilities for outcomes were from available patient data. Health system costs were from the Canadian health care perspective and were based on 2021 Canadian dollars (CAD). The incremental cost-effectiveness ratio (ICER) was expressed as the ratio of incremental cost to quality-adjusted life years (QALY). The impact of parameter uncertainty was investigated using deterministic and probabilistic sensitivity analyses. The base case for SBRT compared with CRT had an ICER of $9,040CAD per QALY gained. Sensitivity analyses demonstrated that the ICER was most sensitive to variations in the utility assigned to “No local failure” ($5,457CAD to $241,051CAD per QALY), adopting low and high estimates of utility and the cost of the SBRT (ICERs ranging from $7345-$123,361CAD per QALY). It was more robust to variations in assumptions around survival and response rate. SBRT is associated with higher upfront costs than CRT. The ICER shows that, within the Canadian health care system, SBRT with 2 fractions is likely to be more cost-effective than CRT.
doi_str_mv 10.1016/j.ijrobp.2023.12.052
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2924999470</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0360301624000221</els_id><sourcerecordid>2924999470</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-3d2d36505d55de52d593432e2bbaf5a9f319cd7e1adb9f8cd303ef1b8d8398343</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVpaDYf_6AUHXuxqw9r1-qhsDVJG0hIySakNyFLY6rFlhzJu7C95Z9X2016LAiERs-8wzwIvaekpITOP61Lt46hHUtGGC8pK4lgb9CM1gtZcCF-vkUzwuek4Bk-RicprQkhlC6qd-iY14zWlRAz9Lz0-MIEHwZn8NLrfpdcwqHDq4ZV2HncaK-t_oyX-E57m7HfYPFq2tjdX-rr3T1uwjDqmMuPbvqVX34LfnIhh-Efuu-dntwWcAa7EPFqdPuPG5h0ygfSGTrqdJ_g_OU-RQ-XF_fN9-L69ttVs7wuDKd0Krhlls8FEVYIC4JZIXnFGbC21Z3QsuNUGrsAqm0ru9pYTjh0tK1tzWWd0VP08ZA7xvC0gTSpwSUDfa89hE1STLJKSlktSEarA2piSClCp8boBh13ihK1l6_W6iBf7eUrylSWn9s-vEzYtAPYf02vtjPw5QBA3nPrIKpkHHgD1kUwk7LB_X_CH3zrl0U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2924999470</pqid></control><display><type>article</type><title>An Economic Analysis of SC24 in Canada: A Randomized Study of SBRT Compared With Conventional Palliative RT for Spinal Metastases</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Kerba, Marc ; Lourenco, Richard De Abreu ; Sahgal, Arjun ; Cardet, Rafael De Feria ; Siva, Shankar ; Ding, Keyue ; Myrehaug, Sten D ; Masucci, Giuseppina L. ; Brundage, Michael ; Parulekar, Wendy R.</creator><creatorcontrib>Kerba, Marc ; Lourenco, Richard De Abreu ; Sahgal, Arjun ; Cardet, Rafael De Feria ; Siva, Shankar ; Ding, Keyue ; Myrehaug, Sten D ; Masucci, Giuseppina L. ; Brundage, Michael ; Parulekar, Wendy R.</creatorcontrib><description>The Canadian Cancer Trials Group (CCTG) Symptom Control 24 protocol (SC.24) was a multicenter randomized controlled phase 2/3 trial conducted in Canada and Australia. Patients with painful spinal metastases were randomized to either 24 Gy/2 stereotactic body radiation therapy (SBRT) or 20 Gy/5 conventional external beam radiation therapy (CRT). The study met its primary endpoint and demonstrated superior complete pain response rates at 3 months following SBRT (35%) versus CRT (14%). SBRT planning and delivery is resource intensive. Given its benefits in SC.24, we performed an economic analysis to determine the incremental cost-effectiveness of SBRT compared with CRT. The trial recruited 229 patients. Cost-effectiveness was assessed using a Markov model taking into account observed survival, treatments costs, retreatment, and quality of life over the lifetime of the patient. The EORTC-QLU-C10D was used to determine quality of life values. Transition probabilities for outcomes were from available patient data. Health system costs were from the Canadian health care perspective and were based on 2021 Canadian dollars (CAD). The incremental cost-effectiveness ratio (ICER) was expressed as the ratio of incremental cost to quality-adjusted life years (QALY). The impact of parameter uncertainty was investigated using deterministic and probabilistic sensitivity analyses. The base case for SBRT compared with CRT had an ICER of $9,040CAD per QALY gained. Sensitivity analyses demonstrated that the ICER was most sensitive to variations in the utility assigned to “No local failure” ($5,457CAD to $241,051CAD per QALY), adopting low and high estimates of utility and the cost of the SBRT (ICERs ranging from $7345-$123,361CAD per QALY). It was more robust to variations in assumptions around survival and response rate. SBRT is associated with higher upfront costs than CRT. The ICER shows that, within the Canadian health care system, SBRT with 2 fractions is likely to be more cost-effective than CRT.</description><identifier>ISSN: 0360-3016</identifier><identifier>ISSN: 1879-355X</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2023.12.052</identifier><identifier>PMID: 38218455</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Canada ; Cancer Pain - economics ; Cancer Pain - etiology ; Cancer Pain - radiotherapy ; Cost-Benefit Analysis ; Female ; Humans ; Male ; Markov Chains ; Middle Aged ; Palliative Care - economics ; Quality of Life ; Quality-Adjusted Life Years ; Radiosurgery - economics ; Spinal Neoplasms - economics ; Spinal Neoplasms - mortality ; Spinal Neoplasms - radiotherapy ; Spinal Neoplasms - secondary ; Spinal Neoplasms - surgery</subject><ispartof>International journal of radiation oncology, biology, physics, 2024-07, Vol.119 (4), p.1061-1068</ispartof><rights>2024 Elsevier Inc.</rights><rights>Copyright © 2024 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c311t-3d2d36505d55de52d593432e2bbaf5a9f319cd7e1adb9f8cd303ef1b8d8398343</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijrobp.2023.12.052$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3541,27915,27916,45986</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38218455$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kerba, Marc</creatorcontrib><creatorcontrib>Lourenco, Richard De Abreu</creatorcontrib><creatorcontrib>Sahgal, Arjun</creatorcontrib><creatorcontrib>Cardet, Rafael De Feria</creatorcontrib><creatorcontrib>Siva, Shankar</creatorcontrib><creatorcontrib>Ding, Keyue</creatorcontrib><creatorcontrib>Myrehaug, Sten D</creatorcontrib><creatorcontrib>Masucci, Giuseppina L.</creatorcontrib><creatorcontrib>Brundage, Michael</creatorcontrib><creatorcontrib>Parulekar, Wendy R.</creatorcontrib><title>An Economic Analysis of SC24 in Canada: A Randomized Study of SBRT Compared With Conventional Palliative RT for Spinal Metastases</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>The Canadian Cancer Trials Group (CCTG) Symptom Control 24 protocol (SC.24) was a multicenter randomized controlled phase 2/3 trial conducted in Canada and Australia. Patients with painful spinal metastases were randomized to either 24 Gy/2 stereotactic body radiation therapy (SBRT) or 20 Gy/5 conventional external beam radiation therapy (CRT). The study met its primary endpoint and demonstrated superior complete pain response rates at 3 months following SBRT (35%) versus CRT (14%). SBRT planning and delivery is resource intensive. Given its benefits in SC.24, we performed an economic analysis to determine the incremental cost-effectiveness of SBRT compared with CRT. The trial recruited 229 patients. Cost-effectiveness was assessed using a Markov model taking into account observed survival, treatments costs, retreatment, and quality of life over the lifetime of the patient. The EORTC-QLU-C10D was used to determine quality of life values. Transition probabilities for outcomes were from available patient data. Health system costs were from the Canadian health care perspective and were based on 2021 Canadian dollars (CAD). The incremental cost-effectiveness ratio (ICER) was expressed as the ratio of incremental cost to quality-adjusted life years (QALY). The impact of parameter uncertainty was investigated using deterministic and probabilistic sensitivity analyses. The base case for SBRT compared with CRT had an ICER of $9,040CAD per QALY gained. Sensitivity analyses demonstrated that the ICER was most sensitive to variations in the utility assigned to “No local failure” ($5,457CAD to $241,051CAD per QALY), adopting low and high estimates of utility and the cost of the SBRT (ICERs ranging from $7345-$123,361CAD per QALY). It was more robust to variations in assumptions around survival and response rate. SBRT is associated with higher upfront costs than CRT. The ICER shows that, within the Canadian health care system, SBRT with 2 fractions is likely to be more cost-effective than CRT.</description><subject>Aged</subject><subject>Canada</subject><subject>Cancer Pain - economics</subject><subject>Cancer Pain - etiology</subject><subject>Cancer Pain - radiotherapy</subject><subject>Cost-Benefit Analysis</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Markov Chains</subject><subject>Middle Aged</subject><subject>Palliative Care - economics</subject><subject>Quality of Life</subject><subject>Quality-Adjusted Life Years</subject><subject>Radiosurgery - economics</subject><subject>Spinal Neoplasms - economics</subject><subject>Spinal Neoplasms - mortality</subject><subject>Spinal Neoplasms - radiotherapy</subject><subject>Spinal Neoplasms - secondary</subject><subject>Spinal Neoplasms - surgery</subject><issn>0360-3016</issn><issn>1879-355X</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1r3DAQhkVpaDYf_6AUHXuxqw9r1-qhsDVJG0hIySakNyFLY6rFlhzJu7C95Z9X2016LAiERs-8wzwIvaekpITOP61Lt46hHUtGGC8pK4lgb9CM1gtZcCF-vkUzwuek4Bk-RicprQkhlC6qd-iY14zWlRAz9Lz0-MIEHwZn8NLrfpdcwqHDq4ZV2HncaK-t_oyX-E57m7HfYPFq2tjdX-rr3T1uwjDqmMuPbvqVX34LfnIhh-Efuu-dntwWcAa7EPFqdPuPG5h0ygfSGTrqdJ_g_OU-RQ-XF_fN9-L69ttVs7wuDKd0Krhlls8FEVYIC4JZIXnFGbC21Z3QsuNUGrsAqm0ru9pYTjh0tK1tzWWd0VP08ZA7xvC0gTSpwSUDfa89hE1STLJKSlktSEarA2piSClCp8boBh13ihK1l6_W6iBf7eUrylSWn9s-vEzYtAPYf02vtjPw5QBA3nPrIKpkHHgD1kUwk7LB_X_CH3zrl0U</recordid><startdate>20240715</startdate><enddate>20240715</enddate><creator>Kerba, Marc</creator><creator>Lourenco, Richard De Abreu</creator><creator>Sahgal, Arjun</creator><creator>Cardet, Rafael De Feria</creator><creator>Siva, Shankar</creator><creator>Ding, Keyue</creator><creator>Myrehaug, Sten D</creator><creator>Masucci, Giuseppina L.</creator><creator>Brundage, Michael</creator><creator>Parulekar, Wendy R.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240715</creationdate><title>An Economic Analysis of SC24 in Canada: A Randomized Study of SBRT Compared With Conventional Palliative RT for Spinal Metastases</title><author>Kerba, Marc ; Lourenco, Richard De Abreu ; Sahgal, Arjun ; Cardet, Rafael De Feria ; Siva, Shankar ; Ding, Keyue ; Myrehaug, Sten D ; Masucci, Giuseppina L. ; Brundage, Michael ; Parulekar, Wendy R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-3d2d36505d55de52d593432e2bbaf5a9f319cd7e1adb9f8cd303ef1b8d8398343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Canada</topic><topic>Cancer Pain - economics</topic><topic>Cancer Pain - etiology</topic><topic>Cancer Pain - radiotherapy</topic><topic>Cost-Benefit Analysis</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Markov Chains</topic><topic>Middle Aged</topic><topic>Palliative Care - economics</topic><topic>Quality of Life</topic><topic>Quality-Adjusted Life Years</topic><topic>Radiosurgery - economics</topic><topic>Spinal Neoplasms - economics</topic><topic>Spinal Neoplasms - mortality</topic><topic>Spinal Neoplasms - radiotherapy</topic><topic>Spinal Neoplasms - secondary</topic><topic>Spinal Neoplasms - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kerba, Marc</creatorcontrib><creatorcontrib>Lourenco, Richard De Abreu</creatorcontrib><creatorcontrib>Sahgal, Arjun</creatorcontrib><creatorcontrib>Cardet, Rafael De Feria</creatorcontrib><creatorcontrib>Siva, Shankar</creatorcontrib><creatorcontrib>Ding, Keyue</creatorcontrib><creatorcontrib>Myrehaug, Sten D</creatorcontrib><creatorcontrib>Masucci, Giuseppina L.</creatorcontrib><creatorcontrib>Brundage, Michael</creatorcontrib><creatorcontrib>Parulekar, Wendy R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kerba, Marc</au><au>Lourenco, Richard De Abreu</au><au>Sahgal, Arjun</au><au>Cardet, Rafael De Feria</au><au>Siva, Shankar</au><au>Ding, Keyue</au><au>Myrehaug, Sten D</au><au>Masucci, Giuseppina L.</au><au>Brundage, Michael</au><au>Parulekar, Wendy R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An Economic Analysis of SC24 in Canada: A Randomized Study of SBRT Compared With Conventional Palliative RT for Spinal Metastases</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2024-07-15</date><risdate>2024</risdate><volume>119</volume><issue>4</issue><spage>1061</spage><epage>1068</epage><pages>1061-1068</pages><issn>0360-3016</issn><issn>1879-355X</issn><eissn>1879-355X</eissn><abstract>The Canadian Cancer Trials Group (CCTG) Symptom Control 24 protocol (SC.24) was a multicenter randomized controlled phase 2/3 trial conducted in Canada and Australia. Patients with painful spinal metastases were randomized to either 24 Gy/2 stereotactic body radiation therapy (SBRT) or 20 Gy/5 conventional external beam radiation therapy (CRT). The study met its primary endpoint and demonstrated superior complete pain response rates at 3 months following SBRT (35%) versus CRT (14%). SBRT planning and delivery is resource intensive. Given its benefits in SC.24, we performed an economic analysis to determine the incremental cost-effectiveness of SBRT compared with CRT. The trial recruited 229 patients. Cost-effectiveness was assessed using a Markov model taking into account observed survival, treatments costs, retreatment, and quality of life over the lifetime of the patient. The EORTC-QLU-C10D was used to determine quality of life values. Transition probabilities for outcomes were from available patient data. Health system costs were from the Canadian health care perspective and were based on 2021 Canadian dollars (CAD). The incremental cost-effectiveness ratio (ICER) was expressed as the ratio of incremental cost to quality-adjusted life years (QALY). The impact of parameter uncertainty was investigated using deterministic and probabilistic sensitivity analyses. The base case for SBRT compared with CRT had an ICER of $9,040CAD per QALY gained. Sensitivity analyses demonstrated that the ICER was most sensitive to variations in the utility assigned to “No local failure” ($5,457CAD to $241,051CAD per QALY), adopting low and high estimates of utility and the cost of the SBRT (ICERs ranging from $7345-$123,361CAD per QALY). It was more robust to variations in assumptions around survival and response rate. SBRT is associated with higher upfront costs than CRT. The ICER shows that, within the Canadian health care system, SBRT with 2 fractions is likely to be more cost-effective than CRT.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>38218455</pmid><doi>10.1016/j.ijrobp.2023.12.052</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0360-3016
ispartof International journal of radiation oncology, biology, physics, 2024-07, Vol.119 (4), p.1061-1068
issn 0360-3016
1879-355X
1879-355X
language eng
recordid cdi_proquest_miscellaneous_2924999470
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Aged
Canada
Cancer Pain - economics
Cancer Pain - etiology
Cancer Pain - radiotherapy
Cost-Benefit Analysis
Female
Humans
Male
Markov Chains
Middle Aged
Palliative Care - economics
Quality of Life
Quality-Adjusted Life Years
Radiosurgery - economics
Spinal Neoplasms - economics
Spinal Neoplasms - mortality
Spinal Neoplasms - radiotherapy
Spinal Neoplasms - secondary
Spinal Neoplasms - surgery
title An Economic Analysis of SC24 in Canada: A Randomized Study of SBRT Compared With Conventional Palliative RT for Spinal Metastases
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T05%3A35%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20Economic%20Analysis%20of%20SC24%20in%20Canada:%20A%20Randomized%20Study%20of%20SBRT%20Compared%20With%20Conventional%20Palliative%20RT%20for%20Spinal%20Metastases&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Kerba,%20Marc&rft.date=2024-07-15&rft.volume=119&rft.issue=4&rft.spage=1061&rft.epage=1068&rft.pages=1061-1068&rft.issn=0360-3016&rft.eissn=1879-355X&rft_id=info:doi/10.1016/j.ijrobp.2023.12.052&rft_dat=%3Cproquest_cross%3E2924999470%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2924999470&rft_id=info:pmid/38218455&rft_els_id=S0360301624000221&rfr_iscdi=true